Articles On Noxopharm (ASX:NOX)

Wall Street slump leads the ASX into an early morning drop. Thanks, Obama Benchmark strides deeper into the red, graceful as a moose on rollerskates New Age Exploration has a mystical moment at the peak of Mount Profit Well, it’s safe to...

Noxopharm (ASX:NOX) has announced what it describes as encouraging new preclinical data from its long-term collaboration with UNSW Sydney.

Biotron commences human trial of COVID-19 Pancreatic trial news from Noxopharm and Clarity Pharma Vectus completes dosing of last cohort   Biotron (ASX:BIT) jumped 6% this morning after announcing the start of a human trial of its lead an...

Local shares will open much lower on Wednesday after a big plunge on Wall Street US CPI came in higher than expected Bitcoin slumps 10pc Local shares are set to plunge on Wednesday morning after a big selloff on Wall Street overnight. At...

Noxopharm (NOX) reports “encouraging” new preclinical data from a dual-cell therapy pancreatic cancer studyThe company received results from its collaboration with UNSW Sydney, where Noxopharm conducted an 18-month trial to test a new drug,...

ASX 200 sinks 2% Small caps get crushed, down 2.5%  Region, AUD and miners sink on weaker China activity   The local market is being dragged to hell by mining, materials and gold stocks, which are down between 4% and 5%. The S&P/ASX...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Noxopharm (ASX:NOX) has announced the addition of three US sites for its CEP-2 sarcoma study - Washington University in St Louis and two Mayo Clinic sites in Florida and Minnesota.

The Victorian Government has granted Noxopharm (ASX:NOX) collaborator Hudson Institute of Medical Research a grant of $1.45 million to fund the joint development program of novel anti-inflammatory compounds.

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

ASX Emerging Companies (XEC) index has closed 1.5% on Tuesday Index now over 10% the better since February 22 Tuesday winners: ResApp (ASX:RAP), RiversGold (ASX:RGL)    The ASX Emerging Companies (XEC) index is 1.5% higher in late trade....

Noxopharm’s (NOX) lead oncology drug Veyonda has been granted Orphan Drug Designation (ODD) by the US Food and Drug Administration (FDA) Veyonda is used to treat soft tissue sarcoma, a broad term for cancers that start in the soft tissues...

An ASX healthcare share is racing into the green today following an update from the US Food and Drug Administration (FDA). The Noxopharm Ltd (ASX: NOX) share price has rocketed 17.19% today and is currently at 38 cents. In earlier trade,...

Highlights The ASX Small Ordinaries index was seen 0.49% up at 3,293.2, by 12:30 PM AEDT. RAP, RGL and NOX were three ASX penny stocks delivering high returns today. Making a consistent gain from penny stocks is not an easy task and i...

Noxopharm (ASX:NOX) has announced that its lead oncology drug candidate Veyonda has been granted Orphan Drug Designation by the US FDA for its use in the treatment of soft tissue sarcoma.

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

ASX to rise, but Wall Street falters on J Powell commments US stocks fell slightly overnight as US Fed chairman Jerome Powell raised the prospect of multiple ‘double-shot’ (50 basis point) rate hikes in 2022, adding that the first one could...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

The study investigates NOX's flagship treatment, Veyonda, in combination with the chemotherapy drug doxorubicin for the treatment of patients with soft tissue sarcoma, an aggressive cancer in urgent need of new treatment options.

The company has a substantial arsenal of products and is channelling more funds into R&D to advance clinical trials, drug discovery and preclinical activities.

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

The clinical-stage drug development company is in a strong financial position following a recent R&D rebate, and is well-placed to advance a promising clinical pipeline.

The ASX has recovered following yesterday’s strong blow, closing up 1.29% with all 11 sectors finishing in the green on lower than normal trading volumes. Today’s biggest sector win was energy, up a nice 2.20% with the financial market foll...

Noxopharm (NOX) receives a $5.8 million cash refund under the Federal Government’s Research and Development rebate for FY21 The refund further strengthens its cash position from $23.6 million on September 30 The company says the refunded c...

The cash injection adds to Noxopharm’s robust cash position, which stood at A$23.6 million as of September 30, 2021.

The ASX is down -0.3% today with the information technology sector taking the cake for the biggest dip at ~3%, followed by the healthcare sector at more than 1.5%. The ASX Emerging Companies Index (XEC) has flatlined. For the second day in...

The ASX 200 Health Index (XHJ) is falling by 1.5% at the time of writing, compared to the broader index which is down by 0.30%. Two ASX-listed companies will be presenting at the annual H.C. Wainwright BIOCONNECT Virtual Conference, to be h...

The Noxopharm Ltd (ASX: NOX) share price has leapt 6% this morning after announcing a change in executive leadership. The move coincides with the drug development company’s goal to position itself on the global stage. At the time of writi...

“Noxopharm is a unique company. I feel very honoured to be chosen as its next CEO and I am excited to lead the company through its next stages,” Dr Mautner said.

Noxopharm Limited (NOX) announces a shift in leadership in preparation for an upcoming ‘growth phase’ Dr Gisela Mautner has been appointed as CEO starting next month, with former CEO Dr Graham Kelly remaining on the board Dr Mautner joined...

Dow Jones hits fresh highs US stocks finished in mixed territories overnight. The Dow index rose 0.59%, but both S&P 500 and Nasdaq slumped by 0.06% and 1.33% respectively. Banks, industrials, and tech stocks led, following more evidenc...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

The Noxopharm Ltd (ASX: NOX) share price is on the rise today after a clinical trial update. Noxopharm shares hit an intraday high of 39 cents, a 6.85% gain, before settling at 37 cents at the time of writing, up 1.37%. Noxopharm is a dru...

The ASX 200 Health Index (XHJ) is trading higher by 0.27% at the time of writing, compared to the broader index which is down by 0.40%. Fertility company Virtus Health (ASX:VRT) is being pursued by a takeover offer from BGH Capital. BGH, wh...

"This phase two study builds on our phase one trial, where we saw promising signals that it may be possible to achieve cancer reduction through the abscopal response,” says CMO.

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Noxopharm (NOX) signs licensing agreement with Hudson Institute of Medical Research for its cutting-edge ribonucleic acid (RNA) technology The licence is subject to clinical trials and marketing approvals for both RNA drug discovery and mR...

Amplia targets human trials for pancreatic cancer drug Noxopharm subsidiary enters licence agreement with Hudson Insitiute of Medical Research $7.2 million placement and $2 million SPP launched by Pharmaxis to support next phase of clinica...

RNA drugs already under development by Hudson will add to existing Pharmorage assets and help position the company at the forefront of chronic inflammatory/autoimmune diseases drug development.

The hot debut of Evolution Energy Minerals (ASX:EV1) was not enough to save the ASX resources sector from falling today. The ASX 200 finished 0.67% down at 7,420 points. All sectors were down except tech, which gained 0.18%. In contrast, mo...

The ASX posted steady gains to start the week on Monday, with investors preferences leaning towards tech/consumer stocks and gold (unusual bedfellows) at the expense of the big banks and iron ore majors. Companies that specialise in the pre...

“This grant not only provides substantial non-dilutive funding to Noxopharm, but it also lends external validation to our work. The MRFF awards a limited number of grants, funding only those projects that are highly rated against a series o...